Pre-transplant assessment of pp65-specific CD4 T cell responses identifies CMV-seropositive patients treated with rATG at risk of late onset infection

Copyright © 2020 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 211(2020) vom: 15. Feb., Seite 108329
1. Verfasser: López-Oliva, Maria O (VerfasserIn)
Weitere Verfasser: Martínez, Virginia, Rodríguez-Sanz, Aranzazu, Álvarez, Laura, Santana, M José, Selgas, Rafael, Jiménez, Carlos, Bellón, Teresa
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial Journal Article Research Support, Non-U.S. Gov't Adaptive immune response Cytokine flow cytometry Cytomegalovirus Immune monitoring Kidney transplant Antilymphocyte Serum Antiviral Agents mehr... Immunosuppressive Agents thymoglobulin D7RD81HE4W Valganciclovir GCU97FKN3R
Beschreibung
Zusammenfassung:Copyright © 2020 Elsevier Inc. All rights reserved.
Assessment of CMV-specific T cell immunity might be a useful tool in predicting CMV infection after solid organ transplantation. We have investigated CD4 and CD8 T-cell responses to CMV pp65 and IE-1 antigens in a prospective study of 28 CMV-seropositive kidney transplant recipients who were administered lymphocyte-depleting antibodies (Thymoglobulin®) as induction treatment and with universal prophylaxis for CMV infection. The response was analyzed by intracellular flow cytometry analysis of IFN-γ production in pretransplant samples and at 1, 6, 12 and 24 months post-transplant. Overall, only pretransplant CD4 T-cell responses to pp65 were significantly lower (p = .004) in patients with CMV replication post-transplant. ROC curve analysis showed that pre-transplant frequencies of pp65-specific CD4 + T cells below 0.10% could predict CMV infection with 75% sensitivity and 83.33% specificity (AUC: 0.847; 95% CI: 0.693-1.001; p = .0054) and seem to be mandatory for efficient control of CMV viral replication by the host immune system. In conclusion, the functional assessment of CMV-specific CD4 T-cell immunity pretransplant in seropositive patients may allow the identification of Thymoglobulin®-treated kidney transplant recipients at risk of developing CMV infection post-transplantation
Beschreibung:Date Completed 04.08.2020
Date Revised 04.08.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2019.108329